Back to search

Article

Impact of a Guaranteed Access Program to Imatinib on the Survival of Patients with Chronic Myeloid Leukemia

2023-04-13

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold>: This work aimed to evaluate the impact of a guaranteed access program to Imatinib on the survival of patients with Chronic Myeloid Leukemia <bold>Methods</bold>: We carried out a retrospective, observational, and analytical study of the database of patients diagnosed with Chronic Myeloid Leukemia of the Instituto Nacional de Cancerología and the Hospital General de...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
66e8852d-e24a-54ce-b056-8d884e53487c
DOI
10.21203/rs.3.rs-2779417/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of a Guaranteed Access Program to Imatinib on the Survival of Patients with Chronic Myeloid LeukemiaDOI 10.21203/rs.3.rs-2779417/v1
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Semantic proximity
Real-Life Data of Patients with Chronic Myeloid Leukemia in AmazonasSemantic proximity
Prognostic factors in patients with chronic myeloid leukemia according to competing-risks analysis: a study based on the SEER databaseSemantic proximity
Best First Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia in Adults: A Network Meta-AnalysisSemantic proximity
CML in the Very Elderly: The Impact of Comorbidities and TKI Selection in a Real-life Multicenter StudySemantic proximity
Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.Semantic proximity
Update on the use of hydroxyurea for the early management of chronic-phase- chronic myeloid leukemia: data from a real-world cohortSemantic proximity
Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on behalf of the Polish Adult Leukaemia GroupSemantic proximity
Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaSemantic proximity
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Semantic proximity
Biomarkers for BCR-ABL1 as a Potential Therapeutic Option Among Adult Chronic Myeloid Leukaemia Treated With Tyrosine Kinase Inhibitors at Molecular Response in Multi-racial Malaysia: Hsa-mir-181a-5p for Decrement; hsa-mir-182-5p and hsa-mir-26a-5p for Increment.Semantic proximity
Select a neighboring publication to make it the new centre.